OHSU

IRB #

IRB00010262

Title

Prospective Evaluation of ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CSF3R

Principal Investigator

Kim-Hien Dao

Study Purpose

Determine the number of patients with chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) who respond to treatment with the study drug ruxolitinib.

Medical Condition(s)

CNL
aCML

Eligibility Criteria

1. Diagnosed with CNL or aCML
2. Platelet count > 25,000 per uL
3. Must be able to discontinue any drug treatment for CNL or aCML
4. Subjects previously treated with ruxolitinib must have pre-treatment cells frozen for genetic analysis
5. Be willing to accept or continue transfusions to treat low hemoglobin levels

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

96 weeks

Minors Included

No

Contact

Nan Subbiah
(503) 494-4603
subbiahn@ohsu.edu

Knight Cancer Institute Clinical Trials Information Line
Email: trials@ohsu.edu
Call: 503-494-1080

Sponsor

n/a

Recruitment End

01/13/2020

Compensation Provided

No


Go Back